HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

gp100(280-288) melanoma antigen peptide

Also Known As:
Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala; YLEPGPVTA; gp(280-288)100 melanoma antigen peptide; tyrosyl-leucyl-glutamyl-prolyl-glycyl-prolyl-valyl-threonyl-alanine
Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Chianese-Bullock, Kimberly A: 2 articles (11/2004 - 11/2004)
2. Deacon, Donna H: 2 articles (11/2004 - 11/2004)
3. Hibbitts, Sarah: 2 articles (11/2004 - 11/2004)
4. Slingluff, Craig L: 2 articles (11/2004 - 11/2004)
5. Eastham, S: 2 articles (10/2001 - 06/2001)
6. Engelhard, V H: 2 articles (10/2001 - 06/2001)
7. Galavotti, H: 2 articles (10/2001 - 06/2001)
8. Grosh, W W: 2 articles (10/2001 - 06/2001)
9. Neese, P: 2 articles (10/2001 - 06/2001)
10. Patterson, J W: 2 articles (10/2001 - 06/2001)

Related Diseases

1. Melanoma (Melanoma, Malignant)
05/05/1999 - "As a model system, we used SCID mice bearing an s.c.-implanted human melanoma line (BLM-gp100) and in vitro-generated CTL specific for the gp100-derived immunogenic peptide YLEPGPVTA, which were injected i.v. with delay. "
10/15/1996 - "In this study, peripheral blood mononuclear cells (PBMCs) were harvested from HLA-A2+ melanoma patients before and after immunization with G9-209 (ITDQVPFSY), G9-280 (YLEPGPVTA), or G9-154 (KTWGQYWQV) peptides in Incomplete Freund's Adjuvant and were tested for the ability to be sensitized in vitro using PBMCs pulsed with the native peptides. "
11/01/2004 - "CTL recognition of the melanoma peptides gp100(154-162) (KTWGQYWQV), gp100(280-288) (YLEPGPVTA), and tyrosinase(369-377D) (YMDGTMSQV) was maintained even when target cells were co-pulsed with equimolar concentrations of peptides with comparable or higher affinity for HLA-A2. "
08/27/1999 - "HLA-A*0201-restricted CTLs from one melanoma patient who has survived metastatic disease recognized MART-1(27-35) (AAGIGILTV), gp100(280-288) (YLEPGPVTA) and gp100(154-162) (KTWGQYWQV) and were cross-reactive on longer peptides that contained these nonamer sequences. "
11/15/2004 - "T-cell responses to the melanoma peptides were observed in 37% of PBL and 38% of SINs in group 1, and in 53% of PBL and 83% of SINs in group 2. The magnitude of T-cell response was higher in group 2. The tyrosinase peptides DAEKSDICTDEY and YMDGTMSQV were more immunogenic than the gp100 peptides YLEPGPVTA and ALLAVGATK. "

Related Drugs and Biologics

1. Peptides (Polypeptides)
2. Epitopes
3. Vaccines
4. Tetanus Toxoid (Vaccine, Tetanus)
5. incomplete Freund's adjuvant
6. Monophenol Monooxygenase (Tyrosinase)
7. HLA-A2 Antigen (HLA A2 Antigen)
8. gp100(17-25) peptide
9. MART-1 Antigen
10. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)